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Summary In breast cancer, several investigations have demonstrated that the tumour biological factors uPA urokinase-type plasminogen
activator) and its inhibitor PAI-1 are statistically independent, strong prognostic factors for disease-free (DFS) and overall survival (OS).
However, statistical analyses performed for varying follow-up periods suggested a time variation of prognostic strength. We therefore
investigated the time-dependent prognostic power of uPA, PAI-1 and steroid hormone receptor status applying the time-varying coefficient
model of Gray. uPA and PAI-1 were analysed by enzyme-linked immunosorbent assay in tumour tissue extracts from 314 breast cancer
patients. Hormone receptors (oestrogen and progesterone) were determined by radioligand binding or by immunohistochemistry. Univariate
and multivariate analyses (Cox proportional hazards model) of DFS and OS were performed for all patients, including 147 node-negative
patients. Median follow-up of patients still alive at time of analysis (n = 232) was 58 months. Although initially of high prognostic impact, a
continuous decrease overtime in the prognostic power of hormone receptor status and uPA was observed. In contrast, the prognostic impact
of PAI-1 increased overtime and reached similarstrength as the lymph node status. The time-dependent risk profile ofprognostic factors may
have important clinical implications in regard to follow-up and patients' individual risk situation. Evaluation of time dependency of prognostic
factors may also give a more profound insight into the dynamics of breast cancer metastasis.
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time variation
Breast cancer is a heterogeneous disease showing great variability
of biological and clinical behaviour. The high prevalence of this
disease in developed countries has stimulated vivid interest in the
exploration and validation of those tumour biological parameters
that may identify patients at risk. In this respect, determination of
the tumour biological factors uPA (urokinase-type plasminogen
activator) and its inhibitor PAI-I is an important issue to address,
as there is substantial evidence that high concentrations of these
factors in primary cancer tissue are conducive to tumour cell
spread and metastasis in breast cancer patients (Duffy et al, 1988;
1990; Janicke et al, 1990; 1991; 1993; 1994; Foekens et al, 1992;
1994; Grondahl-Hansen et al, 1993; Duggan et al, 1995).
uPA and PAI-I are strong and independent prognostic factors in
both node-negative and node-positive patients; elevated antigen
levels of uPA or PAI-I are correlated with short disease-free
survival and early death (Duffy et al, 1990; Janicke et al, 1993;
1994; Foekens et al, 1992; 1994; Grondahl-Hansen et al, 1993;
Duggan et al, 1995). Statistical analyses performed at different
times of follow-up, however, suggest that the prognostic strength
varies with time (Janicke et al, 1990; 1991; 1993; 1994; Altman et
al, 1994). Here, we analyse the time-varying impact of uPA and
PAI-I in addition to that of the traditional biological prognostic
factor, steroid hormone receptor status, on breast cancer prognosis
Received 30 September 1996
Accepted 9January 1997
Correspondence to: M Schmitt
applying the time-varying coefficient model of Gray (1992). In
this model, the effect of variables on relative risk (e.g. in disease-
free survival) is assessed by employing an extension of the Cox
proportional hazards model (Cox, 1972): the coefficient P, which
in the Cox model is assumed to be constant in time, is replaced by
the time-varying function [B(t).
PATIENTS AND METHODS
Patients
In a prospective observational study (1987-91), 314 patients with
invasive breastcancerwere enrolled (Table 1). Fresh tumourtissue
was dissected by the pathologist and representative samples were
snap frozen for subsequent determination of uPA and PAI-1
antigen content. Laboratory and patient data were documented in a
computerized database after completion of primary therapy.
Follow-up data were obtained every 3 months. Primary treatment
was by modified radical mastectomy or by breast-conserving
surgery, including axillary lymph node dissection. Patients with
distant metastases at the time of primary surgery (M1) were not
included in the study. The median number ofaxillary lymph nodes
removed was 18 (5-45) and the median tumour diameter 2.5 cm
(0.5-15 cm). The decision as to whether chemotherapeutic or
hormonal adjuvant therapy should be applied was made strictly
without consideration of uPA and PAI-I antigen tissue levels and
solely based on the general consensus at the time of treatment.
Patients with axillary lymph node involvement received either
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Table 1 Patient's characteristics (n = 314)
Variable Frequency (%)
Menopausal status
Pre/perimenopausal
Post-menopausal
Age (years)
Median
Range
Adjuvant therapy
Chemotherapy
Hormone therapy
Both
No adjuvant therapy
Tumours
Size (cm)
Ti <2
T2 > 2 < 5
T3 > 5
Axillary lymph node status
Negative
Positive
Histological type
Invasive ductal carcinoma
Invasive lobular carcinoma
Others
Steroid hormone receptor status
Positive
Negative
Oestrogen receptor status
Positive
Negative
Progesterone receptor status
Positive
Negative
Grading (Scarff-Bloom-Richardson)
G1/2
G3/4
Vessel invasion
Absent
Present
Tumour necrosis
Absent
Present
118
196
56
27-89
62
108
8
136
103
171
40
147
167
265
34
15
240
74
237
77
205
109
191
123
252
62
216
98
adjuvant chemotherapy (n = 66) and/or adjuvant hormone therapy
with tamoxifen (post-menopausal patients, n = 99); 11 node-posi-
tive patients received no form of adjuvant treatment. In the node-
negative group, 125 patients did not receive any kind of adjuvant
treatment; five patients were subjected to chemotherapy and
17 patients received tamoxifen (see Table 1). Chemotherapy
consisted ofsix cycles ofCMF (cyclophosphamide 600 mg m-2 i.v.
on day 1, methotrexate 40 mg m-2 i.v. on day 1, 5-fluorouracil
600 mg m-2 i.v. on day 1, repeated every 21 days) and hormone
therapy consisted of 30 mg of tamoxifen p.o. daily. The patients
were followed up by clinical visits for 5-93 months (median 52
months) at fixed intervals. Within this time of observation, 102
patients relapsed and 82 patients died. The median duration of
follow-up in patients still alive at time of analysis was 58 months
(range 32-93).
Assays
uPA and PAI-I antigen were determined by a commercially avail-
able ELISA in extracts of breast cancer tissue specimens (uPA,
Imubind no. 894; PAI-1; Imubind no. 821; both from American
Diagnostica, Greenwich, CT, USA) and expressed as ng ofantigen
per mg oftissue protein; steroid hormone receptors (oestrogen and
progesterone receptors) were determined in the cytosol fractions
(n = 294) (Janicke etal, 1990; 1991; 1993; 1994). Specimens were
considered oestrogen or progesterone positive ifthey contained at
least 20 fmol per mg of protein. In 20 tumours, immunohisto-
chemical staining on paraffin-embedded tissue sections was
performed; positive staining denoted receptorpositivity.
Statistical analysis
The prognostic impact ofuPA and PAI-I (disease-free and overall
survival) was first analysed by the Cox proportional hazards
model (Cox, 1972) using the SPSS software package (SPSS,
Chicago, IL, USA) and by the CART Classification and
Regression Trees) technique (Breiman et al, 1984). For this statis-
tical analysis, continuous as well as discrete breast cancer-related
covariates were included, all of which were considered as fixed
(not time dependent). Determination of the optimum cut-off for
uPA and PAI-I to discriminate low-risk and high-risk patients was
performed using log-rank statistics and isotonic regression
(Janicke et al, 1990; 1991; 1993; 1994). The values with maximal
log-rank test were taken for this discrimination. Group-oriented
curves for disease-free and overall survival were calculated
according to Kaplan and Meier (1958). The relative risks associ-
ated with the various prognostic variables after discrimination into
high-risk and low-risk groups were estimated by the Cox propor-
tional hazards model. All tests were performed at a significance
level of a = 0.05. The influence ofadjuvant systemic therapy was
tested by carrying out an additional Cox proportional hazard
analysis including chemotherapy and hormone therapy as 'prog-
nostic variables'. The Cox proportional hazards model is based on
the assumption that the relative risk (RR) associated with a factorx
compared with a factor value x = 0 is described by RR(x) =
exp(,x), with the coefficient independent of time. Prognostic
factors may, however, have a changing influence on disease-free
or overall survival probability with time (Gray, 1992; Lipponen et
al, 1992; Yoshimoto et al, 1993). To reveal the time-varying effect
ofuPA, PAI-1, the steroid hormone receptor status and the axillary
lymph node status on breast cancer prognosis, the extended Cox
proportional hazards model of Gray was applied. In this time-
varying coefficient model, the time constancy assumption on P is
relaxed and it is allowed to be a function oftime, P(t). The relative
risk associated with a factor x is thus modelled by RR(t,x) =
exp (P(t)x). If x is a binary variable, this expression reduces to
RR( t) = exp (5(t)). The function 5(t) is obtained by estimating , at
numerous intervals in time and then smoothing over these point-
wise estimates using spline functions. These analyses were
performed with the S-Plus statistical software package (Statistical
Sciences, 1993).
RESULTS
Breast cancer patients with high levels of either uPA (> 3 ng mg'
protein) or PAI-I (> 14 ng mg' protein) in their primary tumours
(Janicke et al, 1991) have a statistically significant increased risk
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Table 2 Univariate and multivariate analyses (Cox proportional hazards model) of prognostic factors in breast cancer patients
Disease-free survival Overall survival
P-value Relative risk (95 % Cia) P-value Relative Risk (95 % Cli)
Univariate Multivariate Univariate Multivariate
Allpatients (n = 314)b
Lymph node status < 0.0001 < 0.0001 3.0 (1.9-4.6) < 0.0001 < 0.0001 3.0 (1.8-4.9)
(positive vs negative)
PAI-1 (ng mg-' protein) < 0.0001 < 0.0001 2.8 (1.9-4.2) < 0.0001 < 0.0001 3.5 (2.2-5.4)
(> 14 vs . 14)
Hormone receptor status 0.0015 0.0340 1.6 (1.0-2.5) <0.0001 0.0016 2.1 (1.3-3.3)
(negative vs positive)
Node-negative patients (n = 147)c
PAI-1 (ng mg-' protein) <0.0001 <0.0001 4.9 (2.3-10.6) <0.0001 <0.0001 9.5 (3.8-23.8)
(> 14 vs < 14)
aCl = confidence interval.bThe following variables were also of statistical significance judged by univariate analysis and thus included in the Cox model: vessel
invasion, grading, tumour necrosis, uPA and tumour size. None of these variables was of statistical significance in multivariate analysis. cuPA (disease-free
survival) and vessel invasion (overall survival) were also statistically significant in univariate analysis and thus included in the Cox model. In multivariate
analysis uPA and vessel invasion failed to reach statistical significance. Steroid hormone receptor status, grade, menopausal status, tumour size, presence of
tumour necrosis and histological type were not statistically significant in univariate analysis.
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Figure 1 Disease-free survival of 147 node-negative breast cancer patients and time variation of the relative risks of disease recurrence in relation to steroid
hormone receptor status (A), uPA antigen level (B) and PAI-1 antigen level (C). PAI-1, uPA and the steroid hormone receptor status were used as dichotomized
covariates: steroid hormone receptor-negative vs receptor-positive, uPA > 3 ng vs < 3 ng mg-' protein, PAI-1 > 14 ng vs < 14 ng mg-' protein. Disease-free
survival, depicted on the left, was estimated by the Kaplan-Meier rmethod. Time variation of the relative risk of disease recurrence, depicted on the right, was
calculated by the time-varying coefficient model of Gray (1992) and function plots (observation time vs relative risk) were constructed for each risk factor within
a time frame of 6-42 months (shaded area). (--- -), 95% confidence interval. NS, not significant
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Figure 2 Time variation of the relative risks of disease recurrence in relation
to uPA, PAI-1, steroid hormone receptor status and axillary lymph node
status in 314 breast cancer patients. The time-varying coefficient model of
Gray (1992) was applied. PAI-1, uPA, axillary lymph node status (positive vs
negative) and steroid hormone receptor status were included in the model as
dichotomized covariates and a function plot (observation time vs relative risk)
displayed. The vertical bars at the top of the plot represent a frequency plot
of recurrences
of disease recurrence and death as judged by univariate analyses
(Table 2). In order to weight uPA and PAI-I with traditional
prognostic factors (axillary lymph node status, steroid hormone
receptor status, grade, vessel invasion, tumour size, and presence
of tumour necrosis), we made use of the Cox proportional hazards
model for both disease-free and overall survival. Only axillary
lymph node status, PAI-I and steroid hormone receptor status
turned out to be independent and strong prognostic factors. In
node-negative patients, PAI-I is the only independent and strong
prognostic factor (Table 2).
In order to find out why uPA and steroid hormone receptor
status, but not PAI-1, had lost their statistically independent prog-
nostic power at the time of analysis, we analysed the prognostic
influence of uPA, PAI-1, and steroid hormone receptor status in
our group of node-negative patients by applying the time-varying
coefficient model of Gray (1992). The evaluation of this model
was confined to the first 42 months of observation after primary
treatment because only during this time interval were sufficient
numbers of patients and recurrences available for this type of
statistical analysis.
The relative risk of disease recurrence evolves as a function of
time for all three parameters evaluated (Figure 1). We noticed that,
during the period of observation, the prognostic power of the
steroid hormone receptor status decreased steadily, even falling
below a relative risk = 1 after 2 years of follow-up (Figure IA).
This result illustrates that, if patients with steroid hormone
receptor-negative breast cancer survive the first 2 years after
primary treatment without experiencing a recurrence, they have an
up to fivefold higher probability ofbeing cured than patients with
steroid hormone receptor-positive tumours. This finding is illus-
trated in the course of the Kaplan-Meier plot of steroid hormone
receptor status. The curves for disease-free survival ofthe low-risk
and high-risk group begin to converge after a follow-up of 3 years.
For uPA, we found a similar result: high uPA-dependent relative
risks indicate early recurrences, whereas around 32 months after
primary treatment the relative risk of recurrence decreases to
values close to 1 (Figure TB). Evidently, after this time, uPA has
lost its independent prognostic power. The time-varying impact of
PAT-i is opposite to that of uPA and steroid hormone receptor
status (Figure IC). The prognostic impact ofPAI-1 increases with
observation time, reaching a peak level at about 33 months.
Evidently, for uPA and steroid hormone receptor status, high rela-
tive risks indicate early disease recurrence whereas a high PAI-I
risk profile is associated with later relapse.
A similar trend as displayed in Figure 1 for node-negative
patients is demonstrated in Figure 2 for the entire group of breast
cancer patients including those with node-negative and node-posi-
tive disease. Initially, at 6 months, the axillary lymph node status
turns out to be ofhighest prognostic impact. This effect levels off
slightly over time. Similar to node-negative breast cancer, both
steroid hormone receptor status and uPA indicate early disease
recurrence, in contrast to the time-varying impact ofPAI-1, which
increases with the observation time, reaching similar strength in
predicting disease-free survival as the axillary lymph node status.
DISCUSSION
Time dependency ofthe impact ofaxillary lymph node and steroid
hormone receptor status on prognosis in breast cancer patients was
first shown by Gray in 1992. We have applied his modified Cox
model to study the time-varying impact on prognosis of the new
tumour biological factors uPA (urokinase-type plasminogen acti-
vator) and PAI-I (inhibitor type 1 to uPA) and also included the
traditional prognostic factors, axillary lymph node status and
steroid hormone receptor status, in this analysis. The powerofuPA
to predict recurrences was strong in the first 3 years, especially in
node-negative patients, but declined substantially thereafter. This
time-related pattern of uPA was similar to that already described
for steroid hormone receptor status.
In contrast, the prognostic impact of PAI-1 increases over time
and becomes even stronger in predicting disease-free survival than
axillary lymph node status. On the other hand, the relative risk for
recurrence, as indicated by axillary lymph node status, after an
initial decline does not vary essentially throughout the observation
period. In node-negative breast cancer patients, PAI-1 even
prevails as the only independent prognostic factor in our analysis.
Confounding effects of adjuvant therapy might have influenced
these results. Thus, adjuvant therapy was included as a prognostic
variable in the statistical analysis. However, the application of
adjuvant therapy was not an independent risk factor. An interac-
tion between prognostic factors and adjuvant therapy affecting the
outcome ofthe statistical analysis could therefore be excluded.
Invasion and metastasis of solid tumours require the degrada-
tion of the extracellular matrix and of the basement membrane at
the site of the primary tumour and at distant loci. Hence, proteo-
lysis and remodelling ofthe matrix at the metastatic site are essen-
tial. Proteases such as uPA, matrix metalloproteases, cathepsins,
plasmin and thrombin and their inhibitors are involved in these
processes (Schmitt et al, 1992; Brunner et al, 1994). Efficient
tumour cell invasiveness, focal proteolysis and metastasis with
secondary tumour growth are based on a critical balance between
proteases, their cell-surface receptors and inhibitors (Liu et al,
1995). Tumour biological studies have attributed a key role to
uPA, its cell-surface-bound receptor (uPA-R) and PAI-I in these
events. The overexpression of uPA-R in breast cancer cells results
in increased tumour invasion and metastasis in an experimental
model (Xing and Rabbani, 1996). uPA-R is a major binding
protein to the vitronectin-rich extracellular matrix (Kanse et al,
1996). It may in addition regulate the R -integrin function, thus
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influencing cell adhesion and direct migration of adherent cells
(Felsenfeld et al, 1996; Wei et al, 1996). Indeed, in addition to
breast cancer, a strong impact on prognosis of uPA content in
tumour tissue has been observed in many other malignancies, e.g.
cancer of the ovary (Kuhn et al, 1994), stomach (Nekarda et al,
1994; Heiss et al, 1995), colon (Ganesh et al, 1994), lung
(Pedersen et al, 1994), kidney (Hofmann et al, 1996), bladder
(Hasui et al, 1989) and cervix uteri (Kobayashi et al, 1994). It is
rather difficult to understand that the tumour tissue content of the
uPA inhibitor PAI- I on an even larger scale indicates a poor prog-
nosis for the cancer patient. Suggestions to explain these findings
are that PAI-1 is a prerequisite for the matrix formation at the
metastatic site by protecting the tumour against tumour-associated
proteases (Sier et al, 1994). Recent observations indicate an even
broader role for PAI-1 in tumourbiology. It may be involved in the
modulation ofthe uPA-R binding to vitronectin (Kanse et al, 1996)
and is thought to inhibit cell attachment to the extracellular matrix
(Stefansson and Lawrence, 1996), thus enabling tumour cells to
migrate in a stepwise fashion, alternately being attached to the
extracellular matrix or detached from it. These findings underline
the strong effect of PAI-1 on the malignant phenotype of the
tumour cell and are in line with the observation that coexpression
of uPA, its receptor and PAI-I is necessary for focalized and
optimal invasiveness (Estreicher et al, 1990; Liu et al, 1995), as
well as for angiogenic activity (Barbareschi et al, 1995).
Shedding and dissemination of tumour cells is a very common
phenomenon in solid tumours, especially in breast cancer. The
presence of tumour cells distant from the primary tumour,
however, is not a definite sign for later occurrence of distant
metastases. So-called dormant micrometastases may be present for
years and may even disappear spontaneously or develop angio-
genic activity and switch to the expanding, invasive phenotype by
different, unknown stimuli (Holmgren et al, 1995). These stimuli
may also involve, among other things, the plasminogen-activating
system mediated by the tumour cell surface-located receptor for
uPA (uPA-R). Indeed, Heiss et al (1995) in a recent study demon-
strated that the presence of uPA-R on disseminated tumour cells
detected in bone marrow aspirates of gastric cancer patients is a
strong indicator for the development of later clinical metastases.
Thus, the occurrence of clinically detectable metastases seems to
depend on the biological properties of the disseminated tumour
cell. One might speculate that tumour cells exhibiting a high
capacity to synthesize uPA are primarily ofthe invasive phenotype
or will switch early during the course of disease to invasiveness,
whereas those producing high levels of PAI-I will become inva-
sive at a later time. Studying the time variation of the risk associ-
ated with these and other factors may give important insights into
their role in tumour cell dissemination and metastasis.
Ourfindings may still be well short ofchanging clinical practice
at the moment. However, both the absence of steroid hormone
receptors and high uPA tumour levels in breast cancer patients can
be said to be indicators ofearly disease recurrence. In patients with
steroid hormone receptor-negative tumours or tumours with high
uPA content, who remain disease free during the first 2 years of
follow-up, late recurrence tends to be rare. On the other hand,
patients with high PAI-i tumour levels have the highest relative
risk ofrecurrence during the second and third years. In conclusion,
the knowledge of the time-dependent risk profile of prognostic
factors in breast cancer might have important clinical implications
regarding follow-up and the assessment ofthe patient's individual
risk situation.
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